AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04187391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tDCS
Description: Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
Study NCT04187391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language training
Description: patients receive language training
Study NCT04187391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language training
Description: patients receive language training
Study NCT04187391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured cognitive training
Description: patients receive unstructured cognitive training.
Study NCT03354728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03354728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study NCT00877578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-Energie ®, Aliscience society
Description: Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
Study NCT00877578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clinutren 1.5 ®, Nestlé Clinical Nutrition
Description: Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Skipping
Description: No meal
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: French fries
Description: 50g of available carbohydrates meal
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Description: 50g of available carbohydrates meal
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hash browns
Description: 50g of available carbohydrates meal
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: 50g of available carbohydrates meal
Study NCT02820805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beans
Description: 50g of available carbohydrates meal
Study NCT02932839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPort micro-electrode array
Description: Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
Study NCT01651273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-852927
Description: Capsules, Oral, 0.25 mg, Once daily, 28 days
Study NCT01651273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-852927
Description: Capsules, Oral, 1.0 mg, Once daily, 28 days
Study NCT01651273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-852927
Description: Capsules, Oral, 2.5 mg, Once daily, 28 days
Study NCT01651273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, Once daily, 28 days
Study NCT04277455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser ablation of benign thyroid nodule
Description: Ablating symptomatic benign thyroid nodules using laser
Study NCT04117269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External shoe lift
Description: Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
Study NCT02888717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'OSNA stadification during surgery'
Description: The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~* Slices A and C are sent OSNA analysis~* Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~* Free (-): \<250 copies~* Micrometastatic (+): 250 ≤ - \<5,000 copies,~* Macrometastatic (++): ≥ 5000 copies.
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: IXAZOMIB capsules
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT02900651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAK683
Description: Drug: MAK683
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan tablets
Study NCT00730210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: b:placebo
Description: 100 microgram placebo subcutaneous a day for 6 months
Study NCT02921438 — intervention group
Intervention type: DEVICE
Intervention: VitalScan Magnetocardiograph
Description: A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
Study NCT04127383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of Burden of Chronic Conditions (ABCC)-tool
Description: The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide capsules
Study NCT01659658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT00445198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 40 patients with SCLC
Study NCT04577586 — intervention group
Intervention type: OTHER
Intervention: oral contrast
Description: negative oral contrast utilization in PET/CT studies
Study NCT03604289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Study NCT03812861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAMDS bundle
Description: Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
Study NCT01160484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVD-R
Description: 40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
Study NCT04494438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02026232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 200mg twice daily
Study NCT02026232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine Placebo
Description: 200mg placebo twice daily
Study NCT03090581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies CP
Description: Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
Study NCT03090581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies FC
Description: Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
Study NCT03720418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXB-102
Description: Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
Study NCT03720418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imitation Surgical Procedure (ISP)
Description: Participants randomized to the control group in Part B will receive an ISP
Study NCT04639193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)
Study NCT04639193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone tablet (encapsulated)
Study NCT04639193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
Study NCT04639193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine capsule
Study NCT02328703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki Therapy
Description: Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
Study NCT02328703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reiki Therapy
Description: Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
Study NCT01742637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%
Description: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
Study NCT01742637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Gel
Description: Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
Study NCT01742637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
Study NCT01166490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
Study NCT01382602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC-USR
Description: AMDC-USR Treatment
Study NCT01382602 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT01860586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
Study NCT02561143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Atta
Description: Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
Study NCT02561143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat flour
Description: Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
Study NCT02561143 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
Study NCT02561143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
Study NCT02561143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
Study NCT02561143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
Study NCT03813342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training with visual feedback of joint kinematics
Description: Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
Study NCT03357120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up after neoadjuvant chemotherapy
Description: Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated).
Study NCT04395859 — intervention group
Intervention type: PROCEDURE
Intervention: Questionnaire
Description: At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
Study NCT04395859 — intervention group
Intervention type: OTHER
Intervention: Data collection up to 1 year
Description: Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
Study NCT02471859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-3280
Description: GDC-3280 at various doses, depending on the cohort and treatment period
Study NCT02471859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at various doses, depending on the cohort and treatment period
Study NCT03499015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty (BET)
Description: A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
Study NCT03505450 — intervention group
Intervention type: OTHER
Intervention: Population Sample
Description: full sample of recruited participants
Study NCT03505450 — intervention group
Intervention type: OTHER
Intervention: Purposive sample
Description: purposive sample of recruited participants
Study NCT01496716 — intervention group
Intervention type: PROCEDURE
Intervention: Hip arthroplasty
Description: The purpose of hip arthroplasties is to reduce pain and increase mobility.
Study NCT01247714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: T-Diet plus Standard
Description: T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
Study NCT01247714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: T-Diet plus Diabet NP
Description: T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Study NCT01247714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna
Description: GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
Study NCT01247714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novasource
Description: Complete high protein diet for diabetic patients and hyperglycemic
Study NCT02825134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
Study NCT02825134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical aortic valve replacement
Description: Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
Study NCT03847038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preventive strategies advice and dementia risk estimate disclosure
Description: The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
Study NCT03833180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
Study NCT05168917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LIAISON Calprotectin
Description: Immunoassay for fecal calprotectin measurement
Study NCT00647634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release Tablets 3 mg
Description: 3mg, single dose fasting
Study NCT00647634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR® Tablets (3 mg
Description: 3mg, single dose fasting
Study NCT00542841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrocortisone withdrawal
Description: This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
Study NCT03921346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device app (PedAMINES™) 1st drug
Description: To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)